Literature DB >> 589594

Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.

G Rivera, A Green, A Hayes, T Avery, C Pratt.   

Abstract

Thirteen children with disseminated neuroblastoma that had become refractory to conventional chemotherapy were treated with the epipodophyllotoxin VM-26. Three patients developed partial responses (greater than 50% reductions in tumors and in the proportion of tumor cells in bone marrow). Acute nonhematologic toxicity after treatment was minimal. Hematologic toxicity was observed but could not be assessed accurately since most patients had abnormal hematopoiesis due to extensive tumor involvement of bone marrow. These results demonstrate that VM-26, as a single agent, can produce measurable tumor responses in children with neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 589594

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

Review 1.  Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.

Authors:  Daniel M Green; Larry E Kun; Katherine K Matthay; Anna T Meadows; William H Meyer; Paul A Meyers; Sheri L Spunt; Leslie L Robison; Melissa M Hudson
Journal:  Pediatr Blood Cancer       Date:  2013-02-15       Impact factor: 3.167

Review 2.  VM26: phase I and II studies.

Authors:  F R Macbeth
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 3.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Chemotherapy of advanced neuroblastoma: does adriamycin contribute?

Authors:  J Ninane; J Pritchard; J S Malpas
Journal:  Arch Dis Child       Date:  1981-07       Impact factor: 3.791

Review 5.  Epipodophyllotoxins in the treatment of childhood cancer.

Authors:  G K Rivera; C H Pui; V M Santana; C B Pratt; W M Crist
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.

Authors:  J Pritchard; T J McElwain; J Graham-Pole
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.